A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ)

Condition:   Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
Interventions:   Drug: 5-Fluorouracil (5-FU);   Drug: Leucovorin;   Drug: Oxaliplatin;   Biological: Atezolizumab;   Drug: Cobimetinib;   Biological: Ramucirumab;   Drug: Paclitaxel;   Biological: PEGylated recombinant human hyaluronidase (PEGPH20);   Drug: BL-8040;   Drug: Linagliptin;   Biological: Atezolizumab;   Drug: Cobimetinib
Sponsor:   Hoffmann-La Roche
Not yet recruiting - verified September 2017

http://ift.tt/2wpWnaQ